Cell therapy weekly: Nucleus Biologics announces the launch of the sustainable Krakatoa™
This week: Nucleus Biologics announces the launch of the sustainable Krakatoa™, Mirus Bio launches TransIT-VirusGen® SELECT Transfection Kits for large-scale viral vector production and Santhera Pharmaceuticals and SEAL Therapeutics enter an agreement to treat LAMA2-deficient congenital muscular dystrophy.
The news highlights:
Nucleus Biologics announces the launch of the sustainable Krakatoa
Nucleus Biologics (CA, USA), a biotechnology company with the aim to streamline scientific discovery to cure, has announced the launch of their latest product Krakatoa. The first-to-market media maker aims to reduce the environmental impact of the cell and gene therapy industry, allowing researchers to manufacture cell culture media at point of use.
Krakatoa addresses concerns in sustainability by producing 65% less greenhouse gas emissions per 500 mL than conventional media with its biodegradable media pods. The product also reduces the time to delivery of custom media and lowers the total delivered cost as the media is shipped in lightweight, handheld pods rather than bottles or containers. For those interested, Krakatoa will be on display at the American Association for Cancer Research Annual Meeting in New Orleans (LA, USA, 8–13 April 2022).
“The carbon emissions of the pharmaceutical industry are significantly worse than the automotive industry. As we continue to make exciting progress across various markets like cell and gene therapy and synthetic meats, the use of liquid cell culture media will exponentially grow,” commented David Sheehan, Founder and CEO of Nucleus Biologics and Stoic Bio. “The launch of Krakatoa is a paradigm shift and will revolutionize the cell culture media market by providing scientists with not only a fresher, tailored cell culture media, but an environmentally sustainable option, it is time to cure people and planet.”
Mirus Bio launches TransIT-VirusGen SELECT Transfection Kits for large-scale viral vector production
Mirus Bio (WI,USA), a manufacturer of transfection reagents for delivery of nucleic acids to eukaryotic cells, has announced the launch of its TransIT-VirusGen SELECT Transfection Kits. The product will support pre-clinical and process development activities in large-scale viral vector production for cell and gene therapy applications. The kits contain the TransIT-VirusGEN Transfection Reagent, intended to enhance the delivery of packaging and transfer plasmid DNA constructs to suspension and adherent HEK 293 cell types for adeno-associated virus or lentivirus production.
“Demand for cell and gene therapies continues to rise, driving a need to move break-through research into the clinic faster,” commented Dale Gordon, CEO at Mirus Bio. “Our team is addressing these needs with the TransIT-VirusGEN SELECT product line, streamlining process development with seamless transition from discovery to clinical and commercial manufacturing.”
Santhera Pharmaceuticals and SEAL Therapeutics enter agreement to treat LAMA2-deficient congenital muscular dystrophy
Santhera Pharmaceuticals (Pratteln, Switzerland), and SEAL Therapeutics (Basel, Switzerland) have entered a strategic agreement in which they will develop a gene therapy approach to treat LAMA2-deficient congenital muscular dystrophy. The collaboration will allow Santhera to focus resources on advancing its platform compounds towards registration and market entry, with the goal of enabling patients with LAMA2 muscular dystrophy access to this treatment.
“Whilst Santhera has been encouraged by the progress of this preclinical gene therapy program, we remain focused on developing our key pipeline projects vamorolone and lonodelestat. SEAL Therapeutics is well positioned to build on this ground-breaking research and attract a qualified pharmaceutical partner in the gene therapy area,” remarked Dario Eklund, CEO of Santhera.
You might also like:
